On the other hand, we recently reported that treatment with sitagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, attenuated the progression of carotid IMT in insulin-treated patients with T2DM compared with the conventional treatment without increasing the risk of hypoglycemia [8]. The gene discussed is DPP4; the disease is Hypoglycemia.